ArticleCardiac failure review2015
Metabolic Therapy in Heart Failure.
Article in Cardiac failure review, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild-type transthyretin amyloidosis.ESC heart failure · 2025Trial
- Tracking Pathways Linking Obesity with Heart Failure.Nutrients · 2025Review
- Single-cell analysis of chromatin and expression reveals age- and sex-associated alterations in the human heart.Communications biology · 2024Article
- Heart Failure and Drug Therapies: A Metabolic Review.International journal of molecular sciences · 2022Review
- Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion.Oxidative medicine and cellular longevity · 2022Article
- Review
- Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation.Circulation research · 2020 · on this mapReview
- Shenmai Injection Improves Energy Metabolism in Patients With Heart Failure: A Randomized Controlled Trial.Frontiers in pharmacology · 2020Article
- Angina due to coronary artery disease with left ventricular systolic dysfunction.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Metabolic Modulation of Cardiac Metabolism in Heart Failure.Cardiac failure review · 2018Review
- The Cardio- and Neuroprotective Effects of Corvitin and 2-Oxoglutarate in Rats with Pituitrin-Isoproterenol-Induced Myocardial Damage.Biochemistry research international · 2018Article
- Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic impairments play an important role in the development and progression of heart failure. The use of metabolic modulators, the number of which is steadily increasing, may be particularly effective in the treatment of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. This review focuses on the role of metabolic modulators, in particular trimetazidine, as a potential additional medication to conventional medical therapy in heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.